Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea
· Delayed Price · Currency is KRW 1,609.00
+10.00 (0.63%)
At close: Dec 5, 2025
Xcell Therapeutics Revenue
Xcell Therapeutics had revenue of 334.59M KRW in the quarter ending September 30, 2025, a decrease of -26.92%. This brings the company's revenue in the last twelve months to 1.36B, down -29.97% year-over-year. In the year 2024, Xcell Therapeutics had annual revenue of 1.93B with 72.11% growth.
Revenue (ttm)
1.36B
Revenue Growth
-29.97%
P/S Ratio
12.92
Revenue / Employee
n/a
Employees
n/a
Market Cap
17.60B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |